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Cutaneous polyarteritis nodosa is a rare subtype of polyarteritis nodosa that lacks signiﬁcant internal organ involvement. It has a
relapsing remitting nature and usually is less responsive to conventional treatments. We report a case of refractory cutaneous
polyarteritis nodosa who failed three immunosuppressive therapies and three diﬀerent biological agents. He was successfully treated with
two rituximab 1000 mg infusions with a good eﬃcacy and tolerance. This case demonstrates the safety and eﬃcacy of rituximab in
treatment of refractory cutaneous polyarteritis nodosa.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Cutaneous polyarteritis nodosa (cPAN) is a subtype of
polyarteritis nodosa (PAN) characterized by diﬀerent cuta-
neous clinical features such as livedoid lesions, necrotic
ulcers or painful nodules without any evidence of visceral
involvement (Morgan and Schwartz, 2010). It is associated
with relapsing remitting lesions that were less responsive to
conventional treatments. There are no recommendations or
guidelines available to date to manage refractory cPAN.
Herein, we report a case of a refractory cPAN who was
successfully treated with rituximab.http://dx.doi.org/10.1016/j.jdds.2016.05.004
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A 25-year-old man presented with recurrent intermittent
episodes of painful ulcerative lesions (Fig. 1) over both legs
of 4 years duration. He denied any systemic complaints.
There were no clinical features that suggested inﬂamma-
tory bowel diseases. Clinical examination revealed multiple
irregular ulcers of various sizes ranging 2–15 cm over both
legs but more in the right leg. Investigations revealed raised
acute-phase reactants (erythrocyte sedimentation rate
83 mm/h and C-reactive protein 40.2 mg/L). Complete
blood counts (CBC) and chemistry were normal. Rheuma-
toid factor, antinuclear antibody and anti-neutrophilic
cytoplasmic antibody (ANCA), anti-phospholipid antibod-
ies, cryoglobulins and viral markers (HIV/HBsAg/anti-
HCV) were negative. A magnetic resonance arteriogra-
phy/venography (MRA/MRV) of thoracic, abdominal
and extremities were normal. A skin biopsy of the ulcer
showed necrotizing transmural vasculitis of small- and
medium-sized vessels consistent with cPAN. No evidence
of granulomatous inﬂammation or fungal elements was
noticed. He was managed initially with prednisolonebehalf of King Saud University.
ommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Painful initial ulcer at the lateral aspect of the right leg.
Figure 2. Healed ulcer at the lateral aspect of the right leg.
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oid tapering beyond 20 mg daily without relapses can’t be
achieved. Therefore, diﬀerent conventional therapies tried
including azathioprine100 mg/day, mycophenolate mofetil
1500 mg twice a day and methotrexate 15 mg/weekly but
without a signiﬁcant improvement. Subsequently, three dif-
ferent anti-tumor necrosis factor-a (TNF-a) agents, etaner-
cept 50 mg/week for 6 months, adalimumab 40 mg
biweekly for 6 months and inﬂiximab 5 mg/kg/dose for
total 10 doses, were administered but with little beneﬁt.
In view of refractory recurrent cPAN, three pulses of
250 mg of methylprednisolone followed by oral pred-
nisolone at 1 mg/kg/day and two doses of rituximab
(1000 mg) at 2-weekly intervals were initiated. After twoweeks, the patient became pain free and able to walk.
Indeed, a signiﬁcant reduction in the size of vasculitic
ulcers was noted (Fig. 2), along with resolution of raised
acute-phase reactants and the ability to taper prednisolone
doses without recurrence.
3. Discussion
To date, very few cases of adult with refractory cPAN
treated successfully with rituximab are described
(Krishnan et al., 2012; Sonomoto et al., 2008). Our case
illustrates the diﬃculty of management of cPAN. Few data
are available regarding the management of refractory
cPAN and not based on clinical guidelines. Most of time
26 I.A. Al-Homood, M.A. Aljahlan / Journal of Dermatology & Dermatologic Surgery 21 (2017) 24–26conventional immunosuppressive therapies are used before
biological agents. Other drug-regimens included anti-TNF
agents (Valor et al., 2014). However, our patient had a
refractory disease to all commonly used immunosuppres-
sive therapies and thee diﬀerent anti TNF- a agents.
Rituximab is a chimeric monoclonal antibody against the
B cell-speciﬁc antigen CD20. Rituximab is used in treat-
ment of rheumatoid arthritis, ANCA-associated vasculitis
and variable autoimmune diseases. Rituximab has been
well tolerated and eﬀective in this case, since the pain dis-
appeared and the size of ulcers reduced signiﬁcantly and
the healing process was obvious within 2 weeks. Thus,
rituximab could be used for treatment of refractory cuta-
neous polyarteritis nodosa.
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